The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs: Miniperspective
Abstract
Two decades have passed since the rule of five ushered in the concept of "drug-like" properties. Attempts to quantify, correlate, and categorize molecules based on Ro5 parameters evolved into the introduction of efficiency metrics with far reaching consequences in decision making by industry leaders and scientists seeking to discover new medicines. Examination of oral drug parameters approved before and after the original Ro5 analysis demonstrates that some parameters such as clogP and HBD remained constant while the cutoffs for parameters such as molecular weight and HBA have increased substantially over the past 20 years. The time dependent increase in the molecular weight of oral drugs during the past 20 years provides compelling evidence to disprove the hypothesis that molecular weight is a "drug-like" property. This analysis does not validate parameters that have not changed as being "drug-like" but instead calls into question the entire hypothesis that "drug-like" properties exist.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J., & Humblet, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,495
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Quantifying the chemical beauty of drugs
Bickerton, G. R., Paolini, G. V., Besnard, J., Muresan, S., & Hopkins, A. L. (2012) · Nature Chemistry · doi:10.1038/nchem.1243 · Cited by 2,242
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
Ertl, P., & Schuffenhauer, A. (2009) · Journal of Cheminformatics · doi:10.1186/1758-2946-1-8 · Cited by 1,939
Ligand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Enumeration of 166 Billion Organic Small Molecules in the Chemical Universe Database GDB-17
Ruddigkeit, L., van Deursen, R., Blum, L. C., & Reymond, J.-L. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300415d · Cited by 1,505
Prediction of Physicochemical Parameters by Atomic Contributions
Wildman, S. A., & Crippen, G. M. (1999) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci990307l · Cited by 1,464
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450
The base-rate fallacy in probability judgments
Bar-Hillel, M. (1980) · Acta Psychologica · doi:10.1016/0001-6918(80)90046-3 · Cited by 1,183
The role of ligand efficiency metrics in drug discovery
Hopkins, A. L., Keserü, G. M., Leeson, P. D., Rees, D. C., & Reynolds, C. H. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4163 · Cited by 1,181
The productivity crisis in pharmaceutical R&D
Pammolli, F., Magazzini, L., & Riccaboni, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3405 · Cited by 918
Ritchie, T. J., & Macdonald, S. J. F. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.07.014 · Cited by 901
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
Is There a Difference between Leads and Drugs? A Historical Perspective
Oprea, T. I., Davis, A. M., Teague, S. J., & Leeson, P. D. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci010366a · Cited by 769
Property distribution of drug-related chemical databases*
Oprea, T. I. (2000) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1008130001697 · Cited by 628
Estimation of the size of drug-like chemical space based on GDB-17 data
Polishchuk, P. G., Madzhidov, T. I., & Varnek, A. (2013) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-013-9672-4 · Cited by 619
Lipinski, C. A. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.029 · Cited by 609
A Comparison of Physiochemical Property Profiles of Development and Marketed Oral Drugs
Wenlock, M. C., Austin, R. P., Barton, P., Davis, A. M., & Leeson, P. D. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021053p · Cited by 546
Winiwarter, S., Bonham, N. M., Ax, F., Hallberg, A., Lennernäs, H., & Karlén, A. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9810102 · Cited by 453
Ritchie, T. J., Macdonald, S. J. F., Young, R. J., & Pickett, S. D. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2010.11.014 · Cited by 442
Hansch, C., Björkroth, J. P., & Leo, A. (1987) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600760902 · Cited by 438
The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization
Pennington, L. D., & Moustakas, D. T. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01807 · Cited by 408
Molecular Field Extrema as Descriptors of Biological Activity: Definition and Validation
Cheeseright, T., Mackey, M., Rose, S., & Vinter, A. (2006) · Journal of Chemical Information and Modeling · doi:10.1021/ci050357s · Cited by 399
New Modalities for Challenging Targets in Drug Discovery
Valeur, E., Guéret, S. M., Adihou, H., Gopalakrishnan, R., Lemurell, M., Waldmann, H., Grossmann, T. N., & Plowright, A. T. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611914 · Cited by 382
Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection: Miniperspective
DeGoey, D. A., Chen, H.-J., Cox, P. B., & Wendt, M. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00717 · Cited by 378
Characteristic Physical Properties and Structural Fragments of Marketed Oral Drugs
Vieth, M., Siegel, M. G., Higgs, R. E., Watson, I. A., Robertson, D. H., Savin, K. A., Durst, G. L., & Hipskind, P. A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030267j · Cited by 359
Lipophilic Efficiency as an Important Metric in Drug Design
Johnson, T. W., Gallego, R. A., & Edwards, M. P. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00077 · Cited by 349
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets
Doak, B. C., Zheng, J., Dobritzsch, D., & Kihlberg, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01286 · Cited by 335
Time-Related Differences in the Physical Property Profiles of Oral Drugs
Leeson, P. D., & Davis, A. M. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049717d · Cited by 326
Ligand Binding Efficiency: Trends, Physical Basis, and Implications
Reynolds, C. H., Tounge, B. A., & Bembenek, S. D. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701255b · Cited by 319
Young, R. J., Green, D. V. S., Luscombe, C. N., & Hill, A. P. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.06.001 · Cited by 311
Assessing drug-likeness – what are we missing?
Vistoli, G., Pedretti, A., & Testa, B. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.11.007 · Cited by 278
Trends in clinical success rates
Smietana, K., Siatkowski, M., & Møller, M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.85 · Cited by 277
Ursu, O., Rayan, A., Goldblum, A., & Oprea, T. I. (2011) · WIREs Computational Molecular Science · doi:10.1002/wcms.52 · Cited by 276
Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity
Hill, A. P., & Young, R. J. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.05.016 · Cited by 258
Meanwell, N. A. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00043 · Cited by 239
Rossi Sebastiano, M., Doak, B. C., Backlund, M., Poongavanam, V., Over, B., Ermondi, G., Caron, G., Matsson, P., & Kihlberg, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00347 · Cited by 234
Palm, K., Luthman, K., Ungell, A.-L., Strandlund, G., Beigi, F., Lundahl, P., & Artursson, P. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980313t · Cited by 206
Design principles for orally bioavailable drugs
Navia, M. A., & Chaturvedi, P. R. (1996) · Drug Discovery Today · doi:10.1016/1359-6446(96)10020-9 · Cited by 204
Ligand efficiency and fragment-based drug discovery
Bembenek, S. D., Tounge, B. A., & Reynolds, C. H. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.11.007 · Cited by 196
Molecular inflation, attrition and the rule of five
Leeson, P. D. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.018 · Cited by 179
Shultz, M. D. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.08.029 · Cited by 175
Self-citationThe role of molecular size in ligand efficiency
Reynolds, C. H., Bembenek, S. D., & Tounge, B. A. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.038 · Cited by 169
Pye, C. R., Hewitt, W. M., Schwochert, J. A., Haddad, T. D., Townsend, C. E., Etienne, L., Lao, Y., Limberakis, C., Furukawa, A., Mathiowetz, A. M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01483 · Cited by 163
Molecular Property Design: Does Everyone Get It?
Leeson, P. D., & Young, R. J. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00157 · Cited by 162
Similarity Searching Using 2D Structural Fingerprints
Willett, P. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-839-3_5 · Cited by 155
Maggiora, G. M., & Shanmugasundaram, V. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-839-3_2 · Cited by 149
Drug discovery beyond the rule of 5 - Opportunities and challenges
Doak, B. C., & Kihlberg, J. O. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1264385 · Cited by 149
Validity of Ligand Efficiency Metrics
Murray, C. W., Erlanson, D. A., Hopkins, A. L., Keserű, G. M., Leeson, P. D., Rees, D. C., Reynolds, C. H., & Richmond, N. J. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500146d · Cited by 139
Considering the impact drug-like properties have on the chance of success
Yusof, I., & Segall, M. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.02.008 · Cited by 137
Quality guidelines for oral drug candidates: dose, solubility and lipophilicity
Bayliss, M. K., Butler, J., Feldman, P. L., Green, D. V. S., Leeson, P. D., Palovich, M. R., & Taylor, A. J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.07.007 · Cited by 133
Simple Size-Independent Measure of Ligand Efficiency
Nissink, J. W. M. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci900094m · Cited by 125
Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations
Young, R. J., & Leeson, P. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00180 · Cited by 120
Hydrogen bonding descriptors in the prediction of human in vivo intestinal permeability
Winiwarter, S., Ax, F., Lennernäs, H., Hallberg, A., Pettersson, C. E., & Karlén, A. (2002) · Journal of Molecular Graphics and Modelling · doi:10.1016/s1093-3263(02)00163-8 · Cited by 114
Reliability of logP Predictions Based on Calculated Molecular Descriptors: A Critical Review
Erös, D., Kövesdi, I., Őrfi, L., Takács‐Novák, K., Acsády, G., & Kéri, G. (2002) · Current Medicinal Chemistry · doi:10.2174/0929867023369042 · Cited by 113
Dependence of Molecular Properties on Proteomic Family for Marketed Oral Drugs
Vieth, M., & Sutherland, J. J. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0603825 · Cited by 103
Inflation of correlation in the pursuit of drug-likeness
Kenny, P. W., & Montanari, C. A. (2013) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-012-9631-5 · Cited by 81
Practical application of ligand efficiency metrics in lead optimisation
Scott, J. S., & Waring, M. J. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.04.004 · Cited by 63
Sutherland, J. J., Raymond, J. W., Stevens, J. L., Baker, T. K., & Watson, D. E. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300684u · Cited by 58
Advances in computationally modeling human oral bioavailability
Wang, J., & Hou, T. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.001 · Cited by 51
Ligand Efficiency Metrics: Why All the Fuss?
Reynolds, C. H. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.70 · Cited by 28
Ward, D. J., Martino, O. I., Simpson, S., & Stevens, A. J. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002088 · Cited by 23
Ohno, K., Nagahara, Y., Tsunoyama, K., & Orita, M. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100023s · Cited by 17
Medicinal chemistry matters – a call for discipline in our discipline
Johnstone, C. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.010 · Cited by 16
Cited by
Natural products in drug discovery: advances and opportunities
Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., Taskforce, T. I. N. P. S., Orhan, I. E., Banach, M., Rollinger, J. M., Barreca, D., Weckwerth, W., Bauer, R., et al. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00114-z · Cited by 5,392
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
The Structure and Function of DNA G-Quadruplexes
Spiegel, J., Adhikari, S., & Balasubramanian, S. (2020) · Trends in Chemistry · doi:10.1016/j.trechm.2019.07.002 · Cited by 920
“optimal for a small molecule with good pharmacokinetic properties [34,35].”
BackgroundMolecular Sets (MOSES): A Benchmarking Platform for Molecular Generation Models
Polykovskiy, D., Zhebrak, A., Sanchez-Lengeling, B., Golovanov, S., Tatanov, O., Belyaev, S., Kurbanov, R., Artamonov, A., Aladinskiy, V., Veselov, M., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.565644 · Cited by 849
“Similar to SA, descriptor limits in QED have been changing during the last decade and current limits may not cover latest drugs (Shultz, 2018).”
Use of molecular docking computational tools in drug discovery
(2021) · Progress in Medicinal Chemistry · doi:10.1016/bs.pmch.2021.01.004 · Cited by 621
Metadata
- Authors
- Shultz, M. D.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-09-13
- Volume
- 62
- Issue
- 4
- Pages
- 1701-1714
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2891800472
- Cited by
- 434
- References
- 68
- FWCI
- 28.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.